Abstract
BackgroundDrug survival rate is generally accepted as a reliable indicator of both efficacy and safety profile of a biological DMARD.ObjectivesTo evaluate survival rates of certolizumab-pegol (CZP) in ankylosing spondylitis (AS)...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have